FLUAD, a trivalent adjuvanted inactivated flu vaccine specifically developed to address the burden of influenza in adults aged 65 years and over, will be available this year on the National Immunisation Program (NIP).
The adjuvant used in Fluad, MF-59, is known to increase the immunogenicity of vaccines, Seqirus said, adding that the vaccine has proven to be "particularly useful for older adults."
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Feb 18
